AVROBIO, Inc. - Common Stock (AVRO)
1.4000
0.00 (0.00%)
PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/MLinvestorplace.com
Palantir stock is on the rise Thursday as PLTR investors react to a new $19 million contract for the big data and AI company.
Via InvestorPlace · June 20, 2024
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?investorplace.com
NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday.
Via InvestorPlace · June 20, 2024
Why Is Avrobio (AVRO) Stock Moving Today?investorplace.com
Avrobio stock is in the news Thursday as the company prepares for a merger and reverse stock split of AVRO after markets close today.
Via InvestorPlace · June 20, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesdayinvestorplace.com
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning!
Via InvestorPlace · June 20, 2024
AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024investorplace.com
AVRO stock results show that Avrobio beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 13, 2024
Why Avrobio Shares Are Rising Wednesdaybenzinga.com
AVROBIO Inc (NASDAQAVRO) shares are trading higher Wednesday after the company said it will explore strategic alternatives.
Via Benzinga · July 12, 2023
Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartisbenzinga.com
Via Benzinga · May 22, 2023
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · July 12, 2023
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Sessionbenzinga.com
Gainers Healthcare Triangle, Inc. (NASDAQHCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market.
Via Benzinga · July 12, 2023
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · July 12, 2023
Avrobio Touts New Positive Data From Gaucher Disease Gene Therapybenzinga.com
Via Benzinga · December 7, 2022
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · June 7, 2023
Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartisbenzinga.com
Shares of clinical-stage gene therapy company AVROBIO, Inc. (NASDAQAVRO) are trading higher Monday due to its agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis
Via Benzinga · May 22, 2023
Dow Tumbles 100 Points; Micron Technology Shares Plungebenzinga.com
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping over 100 points on Monday. The Dow traded down 0.36% to 33,306.30 while the NASDAQ rose 0.39% to 12,707.21. The S&P 500, also rose, gaining, 0.05% to 4,194.07.
Via Benzinga · May 22, 2023
Nasdaq Rises Over 50 Points; Greenhill Shares Spike Higherbenzinga.com
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining over 50 points on Monday. The Dow traded down 0.20% to 33,359.71 while the NASDAQ rose 0.47% to 12,717.37. The S&P 500, also rose, gaining, 0.15% to 4,198.44.
Via Benzinga · May 22, 2023
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Gainers Greenhill & Co., Inc. (NYSEGHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.
Via Benzinga · May 22, 2023
Why Is AVROBIO (AVRO) Stock Up 83% Today?investorplace.com
AVROBIO (AVRO) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NVS).
Via InvestorPlace · May 22, 2023
Analyst Says Gene Therapy Data Update Offers Insights into Potential Pivotal Endpointsbenzinga.com
Avrobio Inc (NASDAQAVRO) shares are trading higher after the company announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a Phase 1/2 trial of an investigational gene therapy for cystinosis,
Via Benzinga · May 18, 2023
Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Monthsbenzinga.com
Avrobio Inc (NASDAQAVRO) announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a Phase 1/2 trial of an investigational gene therapy for cystinosis,
Via Benzinga · May 18, 2023
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · March 23, 2023
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · January 10, 2023